Released May 15, 2017, after the close
10-Q filed May 15, 2017, 45 days after period end · 0001564590-17-011043
Q1 2017 · 10-Q
Revenue$1.03M$1.03M −22.3% vs Q1 2016±0.0% vs Q4 2016
Net Income-$10.13M-$10.13M N/M vs Q1 2016N/M vs Q4 2016
EPS Diluted-$0.24-$0.24 N/M vs Q1 2016N/M vs Q4 2016
Operating Income-$9,971,000N/M
Operating Cash Flow-$7,455,000N/M
Free Cash Flowderived-$7,610,000N/M
Margins · derived
Operating margin-970.9%−372.1 pt vs Q1 2016
Net margin-986.0%−352.3 pt vs Q1 2016
What the release said
The release
Same quarter
| Metric | Q1 2017 | Q1 2016 | Q1 2015 | Q1 2014 |
|---|---|---|---|---|
| Revenue | $1.03M | $1.32M | — | — |
| Net Income | -$10.13M | -$8.38M | -$7.88M | -$6.98M |
| EPS Diluted | -$0.24 | -$0.29 | -$0.38 | -$0.34 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR